alzheimer's

Biogen Inc (NASDAQ: BIIB) shares, which suffered a severe setback in early 2019 after the company's Alzheimer's program flopped, were seeing a resurgence Tuesday.  The stock fell under the psychological barrier of $300 March 21, when the company and its development partner Eisai...

Shares of thinly-traded nano-cap biotech Neurotrope Inc (NASDAQ: NTRP) were plummeting Monday following an adverse clinical trial readout. What Happened Neurotrope, a biopharma developing therapies for neurodegenerative diseases, said a confirmatory Phase 2 study of Bryostatin-1 in moderate-...

Actor Seth Rogen is famous not only for his acting career, but also for his Alzheimer's organization Hilarity for Charity, founded back in 2012. He first became familiar with the disease after his mother-in-law was diagnosed at age 55. Rogen said the disease is "brutal" and...

A drug to treat Alzheimer's disease is increasingly proving elusive, despite billions of dollars spent on research and development. Johnson & Johnson (NYSE: JNJ)'s Janssen unit; Merck & Co., Inc. (NYSE: MRK); and Eli Lilly And Co (NYSE: LLY) in collaboration with AstraZeneca...

Shares of neuroscience company Biogen Inc (NASDAQ: BIIB) lost more than 25 percent Thursday morning after the company said it will discontinue an ongoing Alzheimer's drug study. What Happened Biogen and its partner Japan-based Eisai said they will discontinue an ongoing global Phase 3...

Clinical-stage biopharmaceutical company Alzheon is set to begin trading on the Nasdaq Global Market under the ticker symbol “ALZH.” The Details The company intends to raise $35 million in common stock through the sale of 2.5 million shares. Alzheon anticipates an initial share...

On Friday's PreMarket Prep trading show, STAT News senior writer Adam Feuerstein weighed in on the results from Biogen Inc (NASDAQ: BIIB) and Eisai's Alzheimer's therapy candidate BAN2401. While BAN2401 failed to show a significant difference from a placebo in a 12-month Phase 2...

Alzheimer's drug research has a high failure rate, and symptoms of the disease start appearing long after amyloid plaques — which are responsible for interruption of cell-to-cell signal transfer — deposit on the brain. The Analyst Roth Capital Partners analyst Robert LeBoyer...

A Morgan Stanley analyst predicts near-term upside for the shares of Denali Therapeutics Inc. (NASDAQ: DNLI), thanks to its work in neuroscience and particularly its lead programs in Parkinson's and Alzheimer's. The Analyst Morgan Stanley analyst Matthew Harrison initiated coverage of...

You've probably heard this before. As early as 2008, several reports, including one published in Molecular Pharmaceutics, began proposing various therapeutic pathways by which cannabinoids could treat Alzheimer’s Disease patients, but none were proven. In 2014, a group of scientists made a...

Neurotrope Inc (NASDAQ: NTRP) announced “positive topline results” for its leading Alzheimer's drug in a press release, but investors weren’t fooled. “The study failed,” Adam Feuerstein, biotech reporter at TheStreet, said Monday on Benzinga’s PreMarket Prep...

Neurotrope Inc (OTC: NTRP), a clinical stage biopharmaceutical company, may have found through its drug Bryostatin a unique solution to addressing Alzheimer's, one of the last major diseases with no cure. Benzinga recently spoke with CEO Dr. Susanne Wilke, ahead of her appearance at the...

AstraZeneca plc (ADR) (NYSE: AZN) shares are trading higher by $1.00 at $27.28 in Friday's session. The primary catalyst for the rally is the announcement that the FDA has accepted duravalumab for priority review status. Also, before the open, the company reported progress with it Alzheimer's drug...

Eli Lilly and Co (NYSE: LLY) fell steeply Wednesday after it announced that its Alzheimer's disease treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3. In a sympathy move, Biogen Inc (NASDAQ: BIIB) also traded notably lower. Is the...

After Eli Lilly and Co (NYSE: LLY) earlier announce the failure of its Alzeheimer’s candidate solanezumab, the entire Alzheimer's sector could feel the aftershocks. While some of the players have since recovered from early morning drops, a few are still in the red in early Wednesday...